Search

Displaying results 2011 - 2020 of 7018 in total
  1. Drug

    Amifostine

    go.drugbank.com/drugs/DB01143
    ApprovedInvestigational

    A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Crinecerfont

    go.drugbank.com/drugs/DB18518
    ApprovedInvestigational

    [A264818] Crinecerfont was approved by the FDA in December 2024 as an adjunct to glucocorticoid replacement in patients with CAH.[L51973,L51993] … [A264818] Crinecerfont is a selective antagonist of corticotropin-releasing factor (CRF) type 1 receptor that works to reduce excessive ACTH secretion from the pituitary.

  3. Drug

    Thioredoxin

    go.drugbank.com/drugs/DB11298
    Approved

    It is a 12-kD oxidoreductase enzyme encoded by TXN and TXN2 genes that contains a dithiol-disulfide active site. … It plays an essential role as an antioxidant in neutralizing food allergens and redox signalling. Allergens containing disulfide bonds are inactivated when reduced by thioredoxin.

  4. Drug

    Colistin

    go.drugbank.com/drugs/DB00803
    ApprovedInvestigational

    It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes.

    Categories: Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index
  5. Drug

    Metharbital

    go.drugbank.com/drugs/DB00463
    ApprovedWithdrawn

    Metharbital is a barbiturate anticonvulsant, similar to phenobarbital, marketed as Gemonil by Abbott Laboratories. It was patented in 1905 by Emil Fischer of Merck.

  6. Drug

    Carbimazole

    go.drugbank.com/drugs/DB00389
    Approved

    An imidazole antithyroid agent. Carbimazole is metabolized to methimazole, which is responsible for the antithyroid activity.

  7. Drug

    Milrinone

    go.drugbank.com/drugs/DB00235
    ApprovedInvestigational

    [A228338, A11759, A228323, A228333, A228348, L31483] Milrinone was originally synthesized at the Sterling Winthrop Research Institute in the 1980s. … [A228333] As a PDE-III inhibitor, milrinone results in increased cAMP levels and improves cardiac function and peripheral vasodilation in acute decongested heart failure.

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Diazoxide

    go.drugbank.com/drugs/DB01119
    ApprovedInvestigational

    Diazoxide is a non-diuretic benzothiadiazine derivative that activates ATP-sensitive potassium channels. … In September 2015, the FDA issued a safety alert regarding post-marketing reports of pulmonary hypertension occurring in infants and neonates.

  9. Drug

    Dronedarone

    go.drugbank.com/drugs/DB04855
    ApprovedInvestigational

    [T28] Commonly marketed as Multaq®, dronedarone was approved by the FDA in July 2009 and Health Canada in August 2009. … A safety concern for the risk of drug-induced hepatocellular injury has been issued following marketing of dronedarone.[L8800]

    Categories: Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  10. Drug

    Relacorilant

    go.drugbank.com/drugs/DB14976
    ApprovedInvestigational

    Originally investigated to manage the metabolic and endocrinologic complications of hypercortisolism, such as Cushing’s syndrome, its clinical utility has pivoted toward oncology as a potent sensitizing … Relacorilant is a first-in-class, selective glucocorticoid receptor antagonist.